Appointments at Elan, Inspire Pharmaceuticals, BioVex and Lux Biosciences – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Management occupations

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Elan, Inspire Pharmaceuticals, BioVex and Lux Biosciences.

Elan ​has hired Eliseo Oreste Salinas​ as executive vice president (EVP) and chief medical officer. Salinas has 20 years of industry experience at companies including Adolor, Shire and Wyeth-Ayerst.

Huw Jones ​has been named CEO of Atlantic Pharmaceuticals​. Most recently Jones was a director of Ardana and has also worked at CV Therapeutics, Elan and SmithKlineBeecham.

Inspire Pharmaceuticals ​has made a number of managerial changes. Kim Brazzell ​is now EVP, medical and scientific affairs; Andrew Koven​ is EVP and chief administrative and legal officer; and Joseph Schachle ​is EVP, pulmonary business.

The other new appointments are: Joseph Spagnardi​, SVP, general counsel and secretary; Thomas Staab​, EVP and chief financial officer; Gerald St Peter​, SVP, ophthalmology business; and Francisca Yanez​, VP, human resources.

Stephen Kelly ​has joined BioVex ​as chief commercial officer. Before joining BioVex Kelly was CEO of Innovive Pharmaceuticals and he has also worked at Amgen, Idec and Sanofi.

Vanda Pharmaceuticals ​has appointed Steven Galson​ to its board of directors. Galson is a former acting US surgeon general and currently SVP for the civilian health operation at Science Applications International Corporation (SAIC).

James Connolly ​has been named as president and CEO of the Aeras Global TB Vaccine Foundation​. Before joining Aeras Connolly was EVP and general manager of Wyeth Vaccines.

Lux Biosciences ​has hired Dean Mitchell ​as president and CEO. Mitchell previously held the same positions at Alpharma and has also worked at Guilford Pharmaceuticals, Bristol-Myers Squibb and GlaxoSmithKline.

John Rossi ​has joined the scientific advisory board at Kylin Therapeutics​. Rossi has more than 30 years of experience working with RNA interference and authored more than 275 peer-reviewed papers.

Related topics Markets & Regulations

Related news

Show more